Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.

Vision Fund sold 4.9 million shares in cancer test developer Guardant Health at more than four times their price in the company's 2018 IPO.

Shin Nippon's migraine treatment spinoff, Satsuma Pharmaceuticals, floated above its range to raise $82.5m in an offering that follows $86m of funding.

Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.

September started out with news on several life sciences companies about to go public as well as a large acquisition deal of another one of them. This space enjoyed a great number of exits last year and the trend appears on a path to be continued through 2019.

GSK’s co-investment partnership with Avalon Ventures has borne fruit with the acquisition of celiac treatment developer Sitari Pharmaceuticals.

Express Scripts is set to exit Mango Health having made a strategic investment in the health management app developer two years ago.

The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

Novartis and Novo helped provide $40m for the autoimmune disease therapy developer that supported its acquisition of joint venture Kanyos Bio.

The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.